Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
  • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/35—Nature of the modification
  • C12N2310/351—Conjugate
  • C12N2310/3513—Protein; Peptide
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
  • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
  • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Definitions

• This invention relates to a system for delivering exogenous nucleic acid into a cell. More particularly, the invention relates to a delivery system, comprising a selected nucleic acid; a hydrophobized, positively- charged, biodegradable polymer; and a lipoprotein, for inserting the selected nucleic acid into a target cell.
• a delivery system comprising a selected nucleic acid; a hydrophobized, positively- charged, biodegradable polymer; and a lipoprotein, for inserting the selected nucleic acid into a target cell.
• Retroviral vectors in particular, have been successfully used for introducing new genes into the genomes of actively dividing cells such that stable transformants are obtained. D.G. Miller et al . , 10 Mol.
• non-viral gene delivery systems such as cationic liposomes, H.M. Te in, 1 Human Gene
• a composition for delivery of a selected nucleic acid into a targeted host cell comprising a complex comprising an effective amount of a hydrophobized, 5 positively charged, biocompatible polymer; an effective amount of a lipoprotein; and an effective amount of the selected nucleic acid.
• the hydrophobized polymer comprises a positively charged biocompatible polymer covalently coupled to a hydrophobic carbon chain moiety.
• a preferred positively charged biocompatible polymer is poly (L-lysine) .
• the hydrophobic carbon chain moiety is preferably a member selected from the group consisting of saturated and unsaturated, straight-chains of C i4 to C 18 , more preferably a stearyl group.
• the lipoprotein is 5 preferably a member selected from the group consisting of low density lipoprotein, high density lipoprotein, and very low density lipoprotein.
• the selected nucleic acid is preferably a plasmid or a synthetic oligonucleotide.
• a plasmid-containing complex a 0 weight ratio of 1:1:1 for hydrophobized polymer: lipoprotein: plasmid is especially preferred.
• oligonucleotide-containing complex a weight ratio of 1:1:0.001-0.05 for hydrophobized polymer -.lipoprotein: oligonucleotide is especially
• the composition preferably has a surface charge in the range of about +2-15 mV, and more preferably about +5 mV.
• a preferred average diameter of the composition is in the range of about 200 to 400 nm, and more preferably about 200 to 300 nm. 0
• a method of transforming a cell in vitro with a selected nucleic acid comprises the steps of:
• composition comprising a complex comprising an effective amount of a hydrophobized, positively charged, biocompatible polymer; an effective 5 amount of a lipoprotein; and an effective amount of the selected nucleic acid.
• contacting the cell with an effective amount of the composition such that the cell internalizes the selected nucleic acid;
• FIG. 1 shows a schematic representation of a lipoprotein component; a hydrophobized, positively- charged, biocompatible polymer; a nucleic acid molecule; and a complex thereof according to the present invention.
• FIGS. 2A-D show, respectively, proton signals generated by X H-NMR due to the e-methylene group in (A) stearyl-poly (L-lysine) (stearyl-PLL) , (B) a mixture of stearyl-PLL and human low density lipoprotein (LDL) , (C) poly (L-lysine) (PLL), (D) a mixture of PLL and LDL.
• FIG. 3 shows circular dichroism spectra of: (a) pSV- ⁇ -gal plasmid DNA; (b) pSV- ⁇ -gal plasmid DNA + LDL; (c) pSV- ⁇ -gal plasmid DNA + LDL + stearyl-PLL, 1:1:1 by weight; (d) pSV- ⁇ -gal plasmid DNA + LDL + stearyl-PLL, 1:1:2 by weight; (e) pSV- ⁇ -gal plasmid DNA + LDL + stearyl-PLL, 1:1:3 by weight; (f) pSV- ⁇ -gal plasmid DNA + LDL + stearyl-PLL, 1:1:4 by weight; (g) pSV- ⁇ -gal plasmid DNA + LDL + stearyl-PLL, 1:1:5 by weight.
• FIG. 4 shows ⁇ -galactosidase activity of lysates of A7R5 smooth muscle cells transformed with a lac * plasmid
• FIG. 5 shows the antiproliferative effect of transformation of A7R5 smooth muscle cells with different amounts of a c-myb antisense oligonucleotide
• references to a complex containing "a polymer” includes a mixture of two or more of such polymers
• reference to "a lipoprotein” includes reference to one or more of such lipoproteins
• reference to "a plasmid” includes reference to two or more of such plasmids .
• an effective amount means an amount of a hydrophobized, positively charged, biocompatible polymer that, when complexed with a lipoprotein and a selected nucleic acid, is sufficient to provide a selected efficiency of delivery of the nucleic acid into a selected mammalian cell with an acceptable level of cytotoxicity.
• An effective amount of lipoprotein is an amount, when complexed with a selected nucleic acid and a hydrophobized polymer, sufficient to provide a selected efficiency of delivery of the selected nucleic acid into a selected mammalian cell with an acceptable level of cytotoxicity.
• an effective amount of a selected nucleic acid is an amount, when complexed with a hydrophobized polymer and a lipoprotein, sufficient to provide a selected efficiency of delivery of the nucleic acid into a selected mammalian cell with an acceptable level of cytotoxicity.
• Such effective amounts of the hydrophobized polymer, lipoprotein, and nucleic acid can vary somewhat depending, for example, on the type of cell used, the nature of the nucleic acid, and the growth conditions of the cell. Such effective amounts can be routinely determined by a person skilled in the art without undue experimentation by following the guidelines set forth herein.
• hydrophobized polymer means a positively charged, biocompatible polymer that is modified by covalent bonding to a hydrophobic carbon chain.
• the positively charged, biocompatible polymer is preferable poly (L-lysine) , poly (D-lysine) , or polyarginine, and more preferably is poly (L-lysine) .
• the molecular weight of the positively charged, biocompatible polymer is preferably in the range of about 500 to 50,000.
• the hydrophobic carbon chain is preferably a saturated or unsaturated straight chain of 14 to 18 carbon atoms. An especially preferred hydrophobic carbon chain is a stearyl group.
• biocompatible means compatible with growth of a cell that is to be or has been transformed with the present composition.
• biocompatible polymers are non-toxic to such cells and are preferably biodegradable .
• lipoprotein means a conjugate comprising a protein portion and a lipid portion.
• Preferred lipoproteins include the classes of lipoproteins known in the art as low density lipoprotein 5 (LDL) , high density lipoprotein (HDL) , and very low density lipoprotein (VLDL) . LDL and HDL are especially preferred.
• the presently claimed composition is effective in delivering a selected nucleic acid into a 0 selected cell by endocytosis mediated by, for example, an LDL or HDL receptor on the surface of the selected cell .
• Efficiency of delivery can be improved by matching a cell having a high number of selected receptors on the surface thereof with a selected 5 lipoprotein.
• efficiency of delivery is improved by matching a cell having a high number of LDL receptors with a complex comprising LDL as the lipoprotein.
• condition favorable for growth mean conditions of temperature, pH, aerobic environment, presence of carbon source, presence of energy source, and the like that permit growth of selected mammalian cells.
• FIG. 1 shows a schematic representation of a gene 5 delivery composition 10 according to the present invention.
• the composition 10 is a complex of a lipoprotein component 12; a hydrophobized, positively- charged, biocompatible polymer 14; and a nucleic acid molecule 16. Hydrophobic interactions between the 0 lipoprotein and the polymer enable the formation of a non-precipitating complex having a wide range of concentrations of the polymer. Such hydrophobic interactions involve the lipid portions of the lipoprotein and the hydrophobized polymer, respectively. 5 Electrostatic interactions between the positively- charged polymer and the negatively-charged nucleic acid molecule allow formation of a condensed DNA-containing complex.
• Such electrostatic interactions involve the positively-charged portions of the positively-charged, hydrophobized polymer and the negatively-charged portions, predominantly the phosphodiester backbone, of the nucleic acid. It has been discovered that the balance between these two interactions is critical to optimizing efficiency of delivery, such that the net hydrophobicity and the surface charge of the complex should be carefully controlled. This balance will be discussed in more detail below.
• Example 1 Stearyl-PLL was synthesized by N-alkylation of poly (L-lysine) (MW 50,000) with stearyl bromide according to the following formula: RNH 2 + R'X ⁇ RNHR' where R is a lysine residue exclusive of the e-amino group, R' is a stearyl group, and X is a halogen, e . g.
• stearyl-PLL having about 18 mole % to about 25 mole % of stearyl groups is preferred for obtaining efficient delivery of nucleic acid into host cells.
• percent of substitution is increased much above about 25 mole %, there is an increase in cytotoxicity of cells treated with the complex. This cytotoxicity is believed due to an increased amount of membrane disruption from the alkyl group bonded to the hydrophobized polymer.
• percent of substitution is decreased much below 18 mole %, there is a decrease in the amount of uptake of the complex by cells, and hence a decrease in the efficiency 5 of delivery.
• Example 2 In this example, PLL, stearyl-PLL, a mixture of PLL and human low density lipoprotein (LDL) , and a mixture of stearyl-PLL and LDL were separately analyzed by -U- 0 NMR. The results of these analyses are shown in FIGS.
• the acyl chains in both the stearyl-PLL and the LDL appear to play an important role in a hydrophobic interaction between these two components in a mixture thereof, which results in the reduction in the peak area of the e-methylene group of the stearyl-PLL 5 when complexed with LDL as compared to the corresponding peak area of stearyl-PLL alone.
• a gene delivery composition according to the present invention was prepared by 0 mixing stearyl-poly (L-lysine) (stearyl-PLL), human low density lipoprotein (LDL) , and pSV- ⁇ -gal plasmid DNA
• Control compositions contained PLL instead of stearyl-PLL. 5 Optical density at 600 nm was measured spectrophotometrically to measure turbidity resulting from aggregation or precipitation of the components . No precipitation or aggregation was observed at wide concentration ranges of stearyl-PLL, LDL, and DNA in PBS . In control compositions containing PLL in place of stearyl-PLL, however, aggregation and/or precipitation was observed.
• compositions containing unmodified PLL instead of stearyl-PLL were unstable as determined by turbidity measurements. It is believed that the hydrophobic interactions between the stearyl-PLL and LDL are responsible at least in part for the formation of the stable DNA-containing complex.
• FIG. 3 shows that the CD spectra of plasmid DNA remained unchanged even though a slight shift in both negative and positive bands at 245 nm and 275 nm, respectively, were observed with the addition of excess stearyl-PLL to the system, e . g. spectra e-g of FIG. 3.
• Denatured control DNA on the other hand, resulted in both of these bands being diminished significantly.
• Example 5 a gene delivery composition comprising stearyl-PLL, LDL, and pSV- ⁇ -gal prepared according to Example 3 in a weight ratio of 1:1:1 was used to examine in vitro delivery and expression of the lacZ gene in a murine smooth muscle cell line, A7R5
• the plasmid pSV- ⁇ -gal 5 (EMBL accession no. X65335) is a positive control vector for monitoring transfection efficiencies of mammalian cells.
• the pSV- ⁇ -gal plasmid comprises an SV40 early promoter and enhancer sequence, transcription start sites, the E. coli lacZ coding region encoding ⁇ - galactosidase, and the SV40 small T antigen polyadenylation signals.
• the SV40 early promoter and enhancer drives transcription of the lacZ gene.
• Cell extracts of transfected cells can be measured directly and easily for ⁇ -galactosidase activity with a spectrophotometric assay.
• the colorigenic indicator 0- nitrophenyl- ⁇ -D-galactopyranoside (ONPG; Sigma Chemical Co., St. Louis, MO) was added to the lysates and incubated an additional 4 hours, and then the OD 40 7 was determined as a measure of ⁇ -galactosidase activity in the transfected cell lysates. J.H. Miller, Experiments in Molecular Genetics (1972); C.V. Hall et al . , 2 J. Mol. Appl. Genet. 101 (1983); P. Norton & J.M. Coffin, 5 Mol. Cell. Biol. 281 (1985).
• Control transfection experiments were done with cationic liposomes (LIPOFECTIN; Gibco BRL) in a 1:1 weight ratio of liposomes to DNA according to the protocol of the supplier. Additional control formulations were PLL/LDL/pSV- ⁇ -gal in a weight ratio of 1:1:1 and stearyl -PLL/pSV- ⁇ -gal in a weight ratio of 1:1.
• FIG. 4 shows the relative ⁇ -galactosidase activity of the composition according to the present invention as compared to various controls.
• the transfection efficiency of the present composition was not affected by the presence of 10% fetal bovine serum, while the efficiency of LIPOFECTIN was decreased by the presence of serum. This result suggests the present composition complexes the DNA such that the DNA is protected from degradation due to nucleases in the serum. Transfection efficiency was increased when lysosomotropic agents such as chloroquine
• FIG. 4 Cytotoxicity due to the stearyl -PLL/LDL/plasmid composition was not observed .
• Example 6 The procedure of Example 5 was followed except that compositions having differing surface charges were used to transform the A7S5 cells. Zeta-potential, i . e . the net surface charge, of the DNA-containing complexes was determined at room temperature using a Malvern Zeta-
• Sizer 3 Conditions for taking these measurements were viscosity of 0.933 and cross beam mode. All of the DNA samples were prepared in PBS. A slightly positive surface charge (about +2-15 mV) provided the highest transfection efficiency with pSV- ⁇ -gal without yielding a significant cytotoxicity problem. An especially preferred surface charge was about +5 mV. With a higher positive charge, higher transfection efficiencies could be obtained, but there was also a simultaneous increase in cytotoxicity. Since cells typically have a negatively charged cell surface, it is believed that the positively charged complexes are attracted by electrostatic interactions to the negatively charged cell surface.
• the net surface charge of a complex can be predicted by knowing the charges of the components that comprise the complex.
• a complex according to the present invention is obtained by mixing the hydrophobized, positively charged, biocompatible polymer; the lipoprotein; and the nucleic acid is selected weight ratios .
• the net surface charge is then measured by determining the zeta potential .
• the net surface charge can then be adjusted, if necessary, to achieve a selected net surface charge by adding more negatively charged nucleic acid or more positively charged hydrophobized polymer .
• Example 5 The procedure of Example 5 was followed except that the size of stearyl-PLL/LDL/plasmid compositions was determined by dynamic laser light scattering (Brookhaven BI-DS) at a 90° angle prior to transfection. Data were analyzed by non-negatively constrained least square analysis. The results of this experiment showed that complexes having an average diameter of about 200 nm resulted in a higher transfection efficiency than complexes having an average diameter of about 400 nm, although such larger complexes were operative for delivery. Preferably, complexes have an average diameter of about 200-400 nm, and more preferably have an average diameter of about 200-300 nm. Notwithstanding this observation, a method of making complexes of a selected average diameter has not yet been developed.
• Example 5 the procedure of Example 5 was followed except that c-myb antisense oligonucleotide
• oligonucleotide complex containing different amounts ( ⁇ g/well) of c-myb antisense oligonucleotide were added to the cells.
• oligonucleotides can be purchased commercially or can be synthesized by methods well known in the art, e . g. R.B.
• FIG. 5 shows that the stearyl - 5 PLL/LDL/oligonucleotide composition resulted in a 50% growth inhibition of smooth muscle cells at a 5 nM concentration of oligonucleotide in the presence of 10% fetal bovine serum.
• a weight ratio of stearyl - PLL/LDL/oligonucleotide of 1:1:0.006 resulted in the 0 highest inhibitory effect.
• Example 10 flow cytometric analysis to investigate internalization of a DNA complex according to the present invention into A7R5 cells was carried 5 out .
• the complex was labeled with either ethidium- bromide-labeled DNA or BIODIPY-labeled LDL (Molecular Probe, cat. no. L-3483) .
• Cells (4 x lO 4 per well) in a 24-well plate were washed twice with PBS, and then fresh growth medium (DMEM) supplemented with 0.1% bovine serum 0 albumin.
• DMEM fresh growth medium
• the cells were then incubated with a 1:1:1 weight ratio of a stearyl-PLL/LDL/pSV- ⁇ -gal complex containing either fluorescence labeled DNA or LDL for 3 hours at 37°C. After washing with PBS three times, the cells were then harvested with trypsin-EDTA and measured 5 for fluorescence intensity (excitation 488nm and emission 594 nm) using a FACscanTM flow
• ADDRESSEE Thorpe, North & Western, L.L.P.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Organic Chemistry (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Public Health (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Dispersion Chemistry (AREA)
• Oncology (AREA)
• Cell Biology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)
• Compositions Of Macromolecular Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24709138

Family Applications (1)

Country Status (8)

Cited By (4)

Families Citing this family (58)

Family Cites Families (2)

• 1996
  • 1996-07-03 US US08/675,120 patent/US5679559A/en not_active Expired - Lifetime
• 1997
  • 1997-07-03 EP EP97934981A patent/EP0958369A4/en not_active Withdrawn
  • 1997-07-03 AU AU38023/97A patent/AU717109B2/en not_active Ceased
  • 1997-07-03 KR KR10-1999-7000048A patent/KR100536979B1/ko not_active Expired - Fee Related
  • 1997-07-03 JP JP10504522A patent/JP2001501812A/ja not_active Ceased
  • 1997-07-03 WO PCT/US1997/012425 patent/WO1998000556A1/en not_active Ceased
  • 1997-07-03 CA CA002259139A patent/CA2259139A1/en not_active Abandoned
  • 1997-07-03 NZ NZ333621A patent/NZ333621A/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events